| 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 对乙酰胺基酚可直压颗粒(元) | 126,992,961.60 | 254,254,607.56 | 114,402,014.35 |
| 对乙酰胺基酚原料药(元) | 80,344,891.90 | 166,107,120.14 | 89,706,582.27 |
| 其他原料药(元) | 10,357,836.32 | 14,531,729.02 | 7,503,303.17 |
| 其他制剂(元) | 3,133,329.85 | 8,000,749.20 | 3,841,208.97 |
| 营业成本(元) | |||
| 对乙酰胺基酚可直压颗粒(元) | 80,828,487.32 | 154,361,464.49 | 66,336,628.37 |
| 对乙酰胺基酚原料药(元) | 47,624,937.85 | 88,094,360.19 | 48,351,546.12 |
| 其他原料药(元) | 6,157,352.56 | 7,725,023.14 | 4,041,505.72 |
| 其他制剂(元) | 2,083,626.61 | 5,475,883.69 | 2,612,934.83 |
| 毛利(元) | |||
| 对乙酰胺基酚可直压颗粒(元) | 46,164,474.28 | 99,893,143.07 | 48,065,385.98 |
| 对乙酰胺基酚原料药(元) | 32,719,954.05 | 78,012,759.95 | 41,355,036.15 |
| 其他原料药(元) | 4,200,483.76 | 6,806,705.88 | 3,461,797.45 |
| 其他制剂(元) | 1,049,703.24 | 2,524,865.51 | 1,228,274.14 |
| 毛利率(%) | |||
| 对乙酰胺基酚可直压颗粒(%) | 36.35 | 39.29 | 42.01 |
| 对乙酰胺基酚原料药(%) | 40.72 | 46.97 | 46.10 |
| 其他原料药(%) | 40.55 | 46.84 | 46.14 |
| 其他制剂(%) | 33.50 | 31.56 | 31.98 |
| 收入构成(%) | |||
| 对乙酰胺基酚可直压颗粒(%) | 57.51 | 57.41 | 53.10 |
| 对乙酰胺基酚原料药(%) | 36.38 | 37.50 | 41.64 |
| 其他原料药(%) | 4.69 | 3.28 | 3.48 |
| 其他制剂(%) | 1.42 | 1.81 | 1.78 |
| 毛利构成(%) | |||
| 对乙酰胺基酚可直压颗粒(%) | 54.87 | 53.35 | 51.07 |
| 对乙酰胺基酚原料药(%) | 38.89 | 41.67 | 43.94 |
| 其他原料药(%) | 4.99 | 3.64 | 3.68 |
| 其他制剂(%) | 1.25 | 1.35 | 1.31 |